Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | SLO | ENG

Naslov:Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : final analysis of the GioTag study
Avtorji:Hochmair, Maximilian J (Avtor)
Morabito, Alessandro (Avtor)
Hao, Desiree (Avtor)
Yang, Cheng-Ta (Avtor)
Soo, Ross A (Avtor)
Yang, James C-H (Avtor)
Gucalp, Rasim (Avtor)
Halmos, Balazs (Avtor)
Märten, Angela (Avtor)
Čufer, Tanja (Avtor)
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment >/=10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Results: Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients.
Ključne besede:non-small cell lung carcinoma -- therapy, drug therapy, afatinib, osimertinib, GioTag study
Leto izida:2020
Založnik:Future Medicine Ltd
Izvor:Velika Britanija
UDK:616-006
ISSN pri članku:1744-8301
OceCobissID:521824025 Povezava se odpre v novem oknu
COBISS_ID:37424899 Povezava se odpre v novem oknu
DOI:10.2217/fon-2020-0740 Povezava se odpre v novem oknu
Opombe:Nasl. z nasl. zaslona; Opis vira z dne 14. 11. 2020; Soavtorica iz Slovenije: Tanja Cufer;
Število ogledov:46
Število prenosov:69
Datoteke:URL URL - Predstavitvena datoteka, za dostop obiščite https://www.futuremedicine.com/doi/pdf/10.2217/fon-2020-0740
 
Nadgradivo:Future oncology
Future Medicine
 
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
Avtorske pravice:C  2020 Maximilian J. Hochmair and other authors
:
  
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.


Licence

Licenca:CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
Opis:Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.
Začetek licenciranja:28.08.2020

Nazaj